GI Genprex, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Genprex, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was disclosed on 15 April 2026 (Cession). Among the most active insiders: Confer Ryan M.. Every trade is openly available.
Analyst consensus: bullish or bearish? Analysts rate Genprex, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 April 2026
All Executives32 Thresholds0 Prospectus0 Other0
Declarations 32 total
▼ Director · Executives · 14 Apr 2026
8 shares @ US$1.23 0.0000% mcap 44.4% of flow Common Stock SEC:0001437749-26-012463:0
▼ Director · Executives · 14 Apr 2026
10 shares @ US$1.23 0.0000% mcap 55.6% of flow Common Stock SEC:0001437749-26-012463:1
● Chief Medical Officer · Executives · 27 Feb 2026
7,168 shares @ US$2.00 65.2% of flow Common Stock SEC:0001437749-26-006154:0
● President, CEO and CFO · Executives · 27 Feb 2026
9,330 shares @ US$2.00 67.6% of flow Common Stock SEC:0001437749-26-006153:0
◆ Director · Executives · 22 Dec 2025
9,000 shares 0Common Stock SEC:0001437749-25-038736:0
◆ President, CEO and CFO · Executives · 22 Dec 2025
45,000 shares 0Common Stock SEC:0001437749-25-038734:0
◆ Director · Executives · 22 Dec 2025
9,000 shares 0Common Stock SEC:0001437749-25-038733:0
◆ Director · Executives · 22 Dec 2025
9,000 shares 0Common Stock SEC:0001437749-25-038732:0
◆ Chief Medical Officer · Executives · 22 Dec 2025
28,500 shares 0Common Stock SEC:0001437749-25-038735:0
● Chief Medical Officer · Executives · 30 Jun 2025
4,500 shares @ US$0.2279 13.4% of flow Common Stock SEC:0001437749-25-021819:0
● President, CEO and CFO · Executives · 30 Jun 2025
5,775 shares @ US$0.2279 14.7% of flow Common Stock SEC:0001437749-25-021817:0
● President, CEO and CFO · Executives · 18 Feb 2025
395 shares @ US$0.41 2.4% of flow Common Stock SEC:0001437749-25-004464:0
● Chief Medical Officer · Executives · 18 Feb 2025
585 shares @ US$0.41 4.1% of flow Common Stock SEC:0001437749-25-004466:0
◆ President, CEO and CFO · Executives · 5 Dec 2024
29,375 shares 0Common Stock SEC:0001437749-24-036880:0
◆ Director · Executives · 5 Dec 2024
4,750 shares 0Common Stock SEC:0001437749-24-036886:0
◆ Director · Executives · 5 Dec 2024
4,750 shares 0Common Stock SEC:0001437749-24-036882:0
◆ Director · Executives · 5 Dec 2024
4,750 shares 0Common Stock SEC:0001437749-24-036884:0
◆ Chief Medical Officer · Executives · 5 Dec 2024
18,250 shares 0Common Stock SEC:0001437749-24-036878:0
● Chief Financial Officer · Executives · 18 Feb 2024
1,126 shares @ US$4.40 71.0% of flow Common Stock SEC:0001437749-24-005055:0
● Chief Medical Officer · Executives · 18 Feb 2024
1,319 shares @ US$4.40 95.9% of flow Common Stock SEC:0001437749-24-005062:0
● Chairman, President and CEO · Executives · 18 Feb 2024
2,642 shares @ US$4.40 37.1% of flow Common Stock SEC:0001437749-24-005058:0
◆ Director · Executives · 27 Jun 2023
123,795 shares 0Common Stock SEC:0001437749-23-018943:0
◆ Director · Executives · 27 Jun 2023
123,795 shares 0Common Stock SEC:0001437749-23-018939:0
◆ Director · Executives · 27 Jun 2023
123,795 shares 0Common Stock SEC:0001437749-23-018941:0
▲ EVP GC Chief Strategy Officer · Executives · 21 Apr 2023
20,000 shares @ US$1.0739 100.0% of flow Common Stock SEC:0001437749-23-010869:0
Canonical exit: 20 Jul 2023 (T+90) 25 of 32 declarations
Load more (7 remaining) About Genprex, Inc. Genprex, Inc. is a biopharmaceutical company focused on developing gene therapies for cancer treatment. It is listed on NASDAQ under the ticker GNPX.